Analysts at Berenberg Bank provided their outlook on CureVac N.V. (NASDAQ:CVAC), mentioning that they believe the withdrawal of first-generation CVnCoV from the approval process effectively removes an overhang from the stock.

According to the analysts, they like the potential of the GlaxoSmithKline (GSK) partnered second-generation COVID-19 vaccine (CV2CoV) and believe it has the potential to capture what they expect will be an active booster market given the virus likely continues to mutate; the emergence of the omicron variant being a prime example of this.